http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#Head
http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#assertion
http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#provenance
http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#pubinfo
http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#assertion
http://purl.obolibrary.org/obo/DOID_0060224
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_0060224
http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00390
http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#association
http://www.w3.org/2000/01/rdf-schema#label
in adults digoxin is indicated for the treatment of mild to moderate heart failure and for the control of resting ventricular rate in patients with chronic atrial fibrillation 1 in pediatric patients with heart failure digoxin increases myocardial contractility digoxin oral solution usp is indicated for the treatment of mild to moderate heart failure digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by increased exercise capacity and decreased heart failure related hospitalizations and emergency care while having no effect on mortality where possible digoxin should be used with a diuretic and an angiotensin converting enzyme inhibitor but an optimal order for starting these three drugs cannot be specified digoxin increases myocardial contractility in pediatric patients with heart failure digoxin oral solution usp is indicated for the control of resting ventricular response rate in patients with chronic atrial fibrillation digoxin should not be used for the treatment of multifocal atrial tachycardia
http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB00390
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#provenance
http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#pubinfo
http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#sig
http://purl.org/nanopub/x/hasSignature
BU+mmas358es4XTFz5yPMRyGZqtXe/rOgTqy1x1cCZOiv0OL/WH/8E1xTbT8aJcQA84iScbCF/aoQ2n1BIX8uJzTwG78LAL/AfLSpM6S7wRsj5OOHHBePd0uPIiI3s2g3du6FmZEyerR7SeLOjYmuy1z325MoHB3DvQABBF1CRw=
http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c
http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c
http://purl.org/dc/terms/created
2021-06-12T16:39:49.728+02:00
http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs